Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabies virus-like particle vaccine
- Development stage
- Preclinical
- Lead developer
- East China University of Science and Technology
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
A preclinical **oral, gut-targeted rabies virus-like particle vaccine** developed by academic researchers for vaccination of rabies animal reservoirs, including stray and wild animals. The antigen comprises rabies virus-like particles self-assembled from rabies virus glycoprotein and matrix protein. The VLPs are co-formulated with the mucosal adjuvant LTB in pH-responsive Eudragit L100 and PLGA microparticles intended to protect the antigen in the stomach and release it in the intestine. In mice, intragastric administration induced antigen-specific humoral, cellular, and mucosal immune responses, including anti-RVLP IgG, IFN-gamma, IL-4, increased CD4-positive and CD8-positive T-cell responses, and intestinal and fecal secretory IgA.
- Other names
- oral gut-targeted rabies virus-like particle vaccineRVLPs + LTB/EPLGA MPs
02
Targets
RABV-G (Rabies virus glycoprotein)M (Rabies virus matrix protein)
Beyond the preview
Go deeper on rabies virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabies virus-like particle vaccine.